Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01093612 · ClinicalTrials.gov registry record · NA
Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer
A NA study of Breast Cancer and Stage IV Breast Cancer, sponsored by City of Hope Medical Center.
- Active
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01093612 is a NA study of Breast Cancer and Stage IV Breast Cancer that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 18 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01093612, a NA study of Breast Cancer and Stage IV Breast Cancer, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab-labeled PET, may help doctors to plan a better treatment PURPOSE: This pilot trial is studying copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab-labeled positron emission tomography (PET) in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Conditions Studied
Interventions
- PROCEDURE Biopsy
- OTHER laboratory biomarker analysis
- PROCEDURE positron emission tomography
- RADIATION copper Cu 64-DOTA-trastuzumab
- OTHER Immunohistochemistry staining method
Study Locations (1)
California
- City of Hope - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-03-16 |
| Est. Completion | 2026-09-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01093612
The ClinicalTrials.gov registry entry for NCT01093612 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Biopsy is the first listed.
NCT01093612 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01093612 about?
NCT01093612 is a clinical study titled "Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer". RATIONALE: Diagnostic procedures, such as copper Cu 64-DOTA-trastuzumab-labeled PET, may help doctors to plan a better treatment PURPOSE: This pilot trial is studying copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab-labeled positron emission tomography (PET) in women with hum...
What is the current status of trial NCT01093612?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 18 participants. The study started on 2011-03-16. Estimated completion is 2026-09-08.
What conditions does trial NCT01093612 study?
This clinical trial studies the following conditions: Breast Cancer, Stage IV Breast Cancer.
What interventions are being tested in trial NCT01093612?
The interventions under investigation include: Biopsy (PROCEDURE), laboratory biomarker analysis (OTHER), positron emission tomography (PROCEDURE), copper Cu 64-DOTA-trastuzumab (RADIATION), Immunohistochemistry staining method (OTHER).
Who is sponsoring clinical trial NCT01093612?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01093612 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.